Announcements Trials
Browse Landscape

Status

Completed 19Unknown 13Recruiting 3Not yet recruiting 3Active not recruiting 3Terminated 2Enrolling by invitation 2

Sponsor Class

OTHER 3

Study Type

Interventional 241Observational 3

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1Ampullary Adenocarcinoma 1

Interventions

Blood Specimen Collection 123Surveys and Questionnaires 82Observation 49Radiotherapy 40Surgical Procedures, Operative 34Drug Therapy 34Biopsy 31Specimen Handling 28Data Collection 27Watchful Waiting 20Interviews as Topic 20Magnetic Resonance Imaging 18Immune Checkpoint Inhibitors 17Liquid Biopsy 16Magnetic Resonance Spectroscopy 15Immunotherapy 15Standard of Care 13pembrolizumab 12Tomography, X-Ray Computed 12Ultrasonography 11trastuzumab deruxtecan 10lenvatinib 10Radiosurgery 10Nivolumab 10Neoadjuvant Therapy 10Carboplatin 10Tissue Banks 9Restraint, Physical 9Radiation 9Endoscopy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Observational × Capecitabine × Clear all
NCT06700382 2024-11-25

NeoTNBCX

Peking University People's Hospital

Recruiting
1,166 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06068023 2023-10-05

ADAPTA

Fondazione Poliambulanza Istituto Ospedaliero

Recruiting
400 enrolled

Ampullary Adenocarcinoma

NCT06035016 2023-09-13

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer

Peking Union Medical College Hospital

Recruiting
300 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡